Search research articles
Contact Us
Filters
Showing results (131-140 of 165) with videos related to
Page
of 17
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 20, 2020
Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa
Lynda Stranix-Chibanda, Peter L Anderson, Deborah Kacanek, et al.
The New England Journal of Medicine
|
July 24, 2024
Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis
Raphael J Landovitz, Sinead Delany-Moretlwe, Jessica M Fogel, et al.
The Lancet. Infectious Diseases
|
July 29, 2014
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study
Robert M Grant, Peter L Anderson, Vanessa McMahan, et al.
Journal of the International AIDS Society
|
October 31, 2025
Evaluation of pharmacokinetic interactions between long-acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084
Mark A Marzinke, Brett Hanscom, Daniel Haines, et al.
Annals of Epidemiology
|
April 11, 2022
Transactional sex, HIV and health among young cisgender men and transgender women who have sex with men in Thailand
Brian W Weir, Chen Dun, Andrea L Wirtz, et al.
Open Forum Infectious Diseases
|
November 3, 2025
Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083
Hannah P Moore, Jessica M Fogel, Mark A Marzinke, et al.
Journal of the International AIDS Society
|
January 3, 2025
Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084
Sinead Delany-Moretlwe, Brett Hanscom, Xu Guo, et al.
Advanced Therapeutics
|
May 17, 2021
Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates
Fernanda P Pons-Faudoa, Antons Sizovs, Kathryn A Shelton, et al.
AIDS Research and Human Retroviruses
|
October 28, 2024
HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084
Jessica M Fogel, Deborah Persaud, Estelle Piwowar-Manning, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 27, 2026
Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083
Raphael J Landovitz, Jessica M Fogel, Fei Gao, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 165) with videos related to
Sort By:
Page
of 17
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 20, 2020
Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa
Lynda Stranix-Chibanda, Peter L Anderson, Deborah Kacanek, et al.
The New England Journal of Medicine
|
July 24, 2024
Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis
Raphael J Landovitz, Sinead Delany-Moretlwe, Jessica M Fogel, et al.
The Lancet. Infectious Diseases
|
July 29, 2014
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study
Robert M Grant, Peter L Anderson, Vanessa McMahan, et al.
Journal of the International AIDS Society
|
October 31, 2025
Evaluation of pharmacokinetic interactions between long-acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084
Mark A Marzinke, Brett Hanscom, Daniel Haines, et al.
Annals of Epidemiology
|
April 11, 2022
Transactional sex, HIV and health among young cisgender men and transgender women who have sex with men in Thailand
Brian W Weir, Chen Dun, Andrea L Wirtz, et al.
Open Forum Infectious Diseases
|
November 3, 2025
Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083
Hannah P Moore, Jessica M Fogel, Mark A Marzinke, et al.
Journal of the International AIDS Society
|
January 3, 2025
Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084
Sinead Delany-Moretlwe, Brett Hanscom, Xu Guo, et al.
Advanced Therapeutics
|
May 17, 2021
Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates
Fernanda P Pons-Faudoa, Antons Sizovs, Kathryn A Shelton, et al.
AIDS Research and Human Retroviruses
|
October 28, 2024
HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084
Jessica M Fogel, Deborah Persaud, Estelle Piwowar-Manning, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 27, 2026
Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083
Raphael J Landovitz, Jessica M Fogel, Fei Gao, et al.
Page
of 17